BivaLirudin versUS Heparin in Extracorporeal Membrane Oxygenation
Status:
Not yet recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
The goal of this open label randomised clinical trial is to compare Bivalirudin versus
Heparin for anticoagulation in patients requiring extracorporeal membrane oxygenation
support.
The main question it aims to answer are include the ability to maintain anticoagulation
within defined therapeutic range, bleeding and thrombotic complications and a comparison of
the total cost of anticoagulation care.
Participants will be randomised to either anticoagulation with Bivalirudin or anticoagulation
with Unfractionated Heparin.